| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | CEO And Director | CEO And Executive Chairman
2 companies
Mendlein John is a Director at aTYR PHARMA INC with holdings across 2 companies. Recent SEC Form 4 filings include 11 buys and 3 sells.
Estimated insider holdings value: $1.3M based on current market prices.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jan 13, 2023 | FATE Fate Therapeutics Inc | Director | Buy | 124,679 | $5.60 | $698,138.49 | +30.8% | +14.8% | -15.7% | |
| Jun 3, 2022 | FATE Fate Therapeutics Inc | Director | Sell | 1,364 | $22.79 | $31,085.56 | -0.9% | +14.3% | -77.8% | |
| Mar 10, 2022 | FATE Fate Therapeutics Inc | Director | Sale+OE | 31,562 | $35.02 | $1,105,200.01 | -8.7% | -31.6% | -86.2% | |
| Dec 21, 2018 | ATYR Atyr Pharma Inc | Director | Buy | 245,000 | $0.42 | $103,247.00 | +31.0% | - | - | |
| Aug 31, 2017 | ATYR Atyr Pharma Inc | CEO And Director | Buy | 37,736 | $2.65 | $100,000.40 | +11.4% | - | - | |
| Apr 24, 2017 | ATYR Atyr Pharma Inc | CEO And Director | Buy | 124 | $3.00 | $372.00 | - | - | - | |
| Apr 20, 2017 | ATYR Atyr Pharma Inc | CEO And Director | Buy | 2,552 | $3.00 | $7,656.00 | +0.4% | - | - | |
| Dec 19, 2016 | ATYR Atyr Pharma Inc | CEO And Director | Buy | 69,000 | $2.20 | $151,662.00 | +27.0% | - | - | |
| Apr 5, 2016 | ATYR Atyr Pharma Inc | CEO And Director | Buy | 2,500 | $3.52 | $8,800.00 | +1.0% | - | - | |
| Apr 5, 2016 | ATYR Atyr Pharma Inc | CEO And Director | Buy | 2,500 | $3.55 | $8,875.00 | +1.0% | - | - |